The European Medicines Agency welcomes the political agreement on the Critical Medicines Act, a major step toward stronger, more resilient supply chains for critical medicines in the EU. The CMA will reinforce manufacturing capacity, address supply chain vulnerabilities, and support better access to essential medicines. EMA is already advancing this work by assessing supply chain vulnerabilities of essential medicines and expanding the European Shortages Monitoring Platform. We look forward to supporting implementation with the European Commission and EU Member States. Find out more about the CMA: https://lnkd.in/eq6zfKvJ EU Health and Food Safety
The political agreement on the Critical Medicines Act is an important step toward stronger and more resilient medicine supply chains in Europe. For Bulgaria, this should be a catalyst for modernizing the national legislative framework, improving coordination between institutions, and creating faster mechanisms to address medicine shortages. Strengthening local capacity and regulatory stability is essential to guarantee sustainable access to critical medicines for patients.
A very important step for strengthening EU healthcare resilience. Secure and reliable access to critical medicines is essential, and the Critical Medicines Act is a strong move toward improving supply chain resilience and reducing shortages across the EU.
Really good to see this moving forward. Medicine shortages have been a real issue across different regions, so anything that strengthens supply chains and monitoring is a big step. I’m especially curious to see how collaboration between the European Medicines Agency, the Commission, and Member States plays out in practice.
Supply chain resilience starts with one certainty: is this medicine the original? One tap. True or False. inforigine.com 😊 @
Medicine shortages and supply chain fragility have shown that access depends not only on innovation, but also on - resilient manufacturing, - strategic sourcing, and - real-time visibility across systems. The Critical Medicines Act appears to be a strong step toward strengthening European health security while improving continuity of patient care. It will be interesting to see how policy, industry, and regulators collaborate to convert resilience goals into sustainable capacity and faster access in practice. This is an important and timely development. Thanks.